A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma
Nina Shah(The University of Texas MD Anderson Cancer Center), Krina K. Patel(University of Vermont), Mary Tagliaferri(Nektar Therapeutics (United States)), Lihua E. Budde(City Of Hope National Medical Center), Julio C. Chávez(Moffitt Cancer Center), Cameron J. Turtle(The University of Sydney), Andrew J. Cowan(University of Washington), Zachary Lee(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Wei Lin(Nektar Therapeutics (United States)), Mario Q. Marcondes(Nektar Therapeutics (United States))
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816